Replies to post #19731 on RespireRx Pharmaceuticals Inc (fka RSPI)

[RBlatch]

Nothing was said specifically to my recollection.

Also, nothing was said about CX1701, I believe it was, not being listed for Vet anymore. It was not on Stoll's pipeline status chart whereas, it was on the last one as well as on the webb site chart.

Cordially,
RBlatch

[erbse24448]

Hi rusbrn,
here a slide from the last presentation. Stoll say nothing at wednesday to the AD pet scan trial. I think he will stop CX 717 after the trial and change to CX 1837 and or CX1739.



Have a nice day
Erbse

[atheroprevent]

nothing positive that I can recall re AD... perhaps some implied administrative or IRB issues because of a mention of possibly having to look at some new sites (don't know whether he was ref to future or present studies), but Stoll's focus was clearly all RD. There are better ears on this board than mine.